Obesity Discussion Forums - View Single Post - Medicine Pipeline- Obesity - Lack of Reimbursement Limits Market Potential

Obesity Discussion · 12-19-06, 11:16 PM

Commercial and Pipeline Perspectives: Obesity - Lack of Reimbursement Limits Market Potential

Introduction
Datamonitor predicts a somewhat enthusiastic uptake of two agents currently in development by 2015. However, reimbursement is critical to the uptake of new medication, due to the high cost of therapy. If the reimbursable status is not achieved, the expansion of the market will not match the rate of growth of the obese population and the great potential of the obesity market will remain untapped.

Scope

Assessment of the patient potential for developmental anti-obesity agents over the period 2006-15
Overview of the anti-obesity R&D pipeline, with detailed information on the classes in development and comparator drugs
Commercial analysis of key compounds in development regarding their ability to take away market share from the currently available drugs
Sales forecasts for key late-stage developmental anti-obesity agents in the seven major markets to 2015

Highlights
The obesity "epidemic" is taking place to a certain extent in all the major markets, and the rate of obesity prevalence growth is not showing any signs of slowing down in the near future.
The anti-obesity market growth does not follow the growth of obesity prevalence. The major cause for the lack of growth in most of the major markets is lack of reimbursement for pharmacological management of obesity.
The drugs currently available in the major markets for treatment of obesity have significant unmet needs and do not meet the expectations of obese patients. The pipeline drugs will be able to expand the market. However, the growth of the market will still be marginal in comparison to the growth of obesity prevalence.

Obesity and Diet Pills

12-19-06, 11:16 PM	#1 (permalink)
Obesity Discussion Administrator Join Date: Jan 2005 Location: Phoenix, AZ Posts: 7,851 Weight Statistics 8/1/2006 Start Date: 185 lb Start Weight: 152 lb Current Weight: 155 lb Goal Weight: -33 lb Weight Loss: 5/1/2007 Goal Date:	Medicine Pipeline- Obesity - Lack of Reimbursement Limits Market Potential Commercial and Pipeline Perspectives: Obesity - Lack of Reimbursement Limits Market Potential Introduction Datamonitor predicts a somewhat enthusiastic uptake of two agents currently in development by 2015. However, reimbursement is critical to the uptake of new medication, due to the high cost of therapy. If the reimbursable status is not achieved, the expansion of the market will not match the rate of growth of the obese population and the great potential of the obesity market will remain untapped. Scope Assessment of the patient potential for developmental anti-obesity agents over the period 2006-15 Overview of the anti-obesity R&D pipeline, with detailed information on the classes in development and comparator drugs Commercial analysis of key compounds in development regarding their ability to take away market share from the currently available drugs Sales forecasts for key late-stage developmental anti-obesity agents in the seven major markets to 2015 Highlights The obesity "epidemic" is taking place to a certain extent in all the major markets, and the rate of obesity prevalence growth is not showing any signs of slowing down in the near future. The anti-obesity market growth does not follow the growth of obesity prevalence. The major cause for the lack of growth in most of the major markets is lack of reimbursement for pharmacological management of obesity. The drugs currently available in the major markets for treatment of obesity have significant unmet needs and do not meet the expectations of obese patients. The pipeline drugs will be able to expand the market. However, the growth of the market will still be marginal in comparison to the growth of obesity prevalence. Obesity and Diet Pills __________________